GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » Cyclically Adjusted Price-to-FCF

Genmab AS (LTS:0MGB) Cyclically Adjusted Price-to-FCF : 27.01 (As of Jun. 05, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Genmab AS Cyclically Adjusted Price-to-FCF?

As of today (2025-06-05), Genmab AS's current share price is kr1437.75. Genmab AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was kr53.24. Genmab AS's Cyclically Adjusted Price-to-FCF for today is 27.01.

The historical rank and industry rank for Genmab AS's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LTS:0MGB' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 22.95   Med: 151.32   Max: 24633.33
Current: 26.95

During the past years, Genmab AS's highest Cyclically Adjusted Price-to-FCF was 24633.33. The lowest was 22.95. And the median was 151.32.

LTS:0MGB's Cyclically Adjusted Price-to-FCF is ranked better than
74.76% of 103 companies
in the Biotechnology industry
Industry Median: 49.09 vs LTS:0MGB: 26.95

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Genmab AS's adjusted free cash flow per share data for the three months ended in Mar. 2025 was kr27.734. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is kr53.24 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Genmab AS's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Cyclically Adjusted Price-to-FCF Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 163.66 135.23 110.07 56.54 29.91

Genmab AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.86 40.42 34.77 29.91 25.10

Competitive Comparison of Genmab AS's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

Genmab AS Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Genmab AS's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=1437.75/53.24
=27.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Genmab AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=27.734/120.2000*120.2000
=27.734

Current CPI (Mar. 2025) = 120.2000.

Genmab AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -2.018 100.300 -2.418
201509 2.219 100.200 2.662
201512 4.019 99.800 4.841
201603 -0.214 100.200 -0.257
201606 3.317 100.600 3.963
201609 3.308 100.200 3.968
201612 -2.066 100.300 -2.476
201703 12.071 101.200 14.337
201706 9.147 101.200 10.864
201709 0.789 101.800 0.932
201712 4.095 101.300 4.859
201803 7.005 101.700 8.279
201806 1.395 102.300 1.639
201809 -3.135 102.400 -3.680
201812 2.869 102.100 3.378
201903 10.115 102.900 11.816
201906 2.840 102.900 3.317
201909 3.698 102.900 4.320
201912 2.606 102.900 3.044
202003 28.192 103.300 32.804
202006 2.019 103.200 2.352
202009 77.280 103.500 89.749
202012 -8.176 103.400 -9.504
202103 17.269 104.300 19.902
202106 4.395 105.000 5.031
202109 4.971 105.800 5.648
202112 1.943 106.600 2.191
202203 8.142 109.900 8.905
202206 12.802 113.600 13.546
202209 27.093 116.400 27.977
202212 8.539 115.900 8.856
202303 48.402 117.300 49.599
202306 4.864 116.400 5.023
202309 27.552 117.400 28.209
202312 28.478 116.700 29.332
202403 22.584 118.400 22.927
202406 22.600 118.500 22.924
202409 33.200 118.900 33.563
202412 33.244 118.900 33.607
202503 27.734 120.200 27.734

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab AS  (LTS:0MGB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Genmab AS Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Genmab AS's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » Cyclically Adjusted Price-to-FCF
Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines